clonazepam has been researched along with busulfan in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Iannetti, P; Meloni, G; Pinto, RM; Raucci, U; Spalice, A; Vignetti, M | 1 |
| Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Maiello, A; Polchi, P | 1 |
| Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS | 1 |
| Diaz, MA; Madero, L; Vicent, MG | 1 |
| Bekassy, A; Hassan, M; Hassan, Z; Jonsson, EN; Karlsson, MO; Ljungman, P; Nilsson, C; Oberg, G; Ringden, O; Sandström, M | 1 |
| Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N | 1 |
| Bacigalupo, A; Buzyn, A; Cahn, JY; Carreras, E; Kröger, N; Puozzo, C; Sanz, G; Vernant, JP | 1 |
| Blanquer, M; Diaz-Carrasco, MS; Moraleda, JM; Olmos, R; Sánchez-Salinas, A; Velasco, J | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Shirai, R; Terashima, K; Tomizawa, D; Tsujimoto, SI; Uchiyama, T; Utano, T | 1 |
1 review(s) available for clonazepam and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for clonazepam and busulfan
| Article | Year |
|---|---|
High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Diseases; Bone Neoplasms; Busulfan; Child; Child, Preschool; Clonazepam; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Topics: Adolescent; Adult; Alkylating Agents; Anticonvulsants; Busulfan; Clonazepam; Cyclophosphamide; Drug Interactions; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Phenytoin; Prospective Studies; Seizures; Transplantation Conditioning; Young Adult | 2010 |
11 other study(ies) available for clonazepam and busulfan
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Barbiturates; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Clonazepam; Combined Modality Therapy; Cyclophosphamide; Electroencephalography; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Middle Aged; Myoclonus; Nervous System Diseases; Prospective Studies | 1992 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Clonazepam; Coma; Combined Modality Therapy; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hemosiderosis; Humans; Hypertension; Immunosuppressive Agents; Incidence; Infant; Liver Diseases; Magnesium Deficiency; Magnetic Resonance Imaging; Male; Nervous System Diseases; Retrospective Studies; Risk Factors; Seizures; Tomography, X-Ray Computed; Transplantation Conditioning; Treatment Failure; Vision Disorders | 1996 |
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Clonazepam; Combined Modality Therapy; Contraindications; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Neoplasm Metastasis; Phenytoin; Remission Induction; Sarcoma, Ewing; Seizures; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 1997 |
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Area Under Curve; Bayes Theorem; Body Fluid Compartments; Body Weight; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Clonazepam; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Genetic Variation; Humans; Infant; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Phenytoin; Seizures; Transplantation Conditioning; User-Computer Interface; Whole-Body Irradiation | 2001 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Clonazepam; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Retrospective Studies; Risk Factors; Sarcoma; Seizures; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2008 |
Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anticonvulsants; Busulfan; Clonazepam; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Seizures; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Clonazepam; Female; Hematopoietic Stem Cell Transplantation; Humans; Levetiracetam; Male; Retrospective Studies; Seizures; Treatment Outcome | 2020 |